Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1026

1.

A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging.

Kaissis G, Ziegelmayer S, Lohöfer F, Algül H, Eiber M, Weichert W, Schmid R, Friess H, Rummeny E, Ankerst D, Siveke J, Braren R.

Eur Radiol Exp. 2019 Oct 17;3(1):41. doi: 10.1186/s41747-019-0119-0.

PMID:
31624935
2.

Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of pro-tumorigenic immune cells.

Mota Reyes C, Teller S, Muckenhuber A, Konukiewitz B, Safak O, Weichert W, Friess H, Ceyhan GO, Demir IE.

Clin Cancer Res. 2019 Oct 4. pii: clincanres.1864.2019. doi: 10.1158/1078-0432.CCR-19-1864. [Epub ahead of print]

PMID:
31585935
3.

The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma.

Kornberg A, Witt U, Schernhammer M, Kornberg J, Müller K, Friess H, Thrum K.

J Surg Oncol. 2019 Oct 2. doi: 10.1002/jso.25721. [Epub ahead of print]

PMID:
31578753
4.

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.

Kaissis G, Ziegelmayer S, Lohöfer F, Steiger K, Algül H, Muckenhuber A, Yen HY, Rummeny E, Friess H, Schmid R, Weichert W, Siveke JT, Braren R.

PLoS One. 2019 Oct 2;14(10):e0218642. doi: 10.1371/journal.pone.0218642. eCollection 2019.

5.

Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis.

Lu M, Hartmann D, Braren R, Gupta A, Wang B, Wang Y, Mogler C, Cheng Z, Wirth T, Friess H, Kleeff J, Hüser N, Sunami Y.

BMC Cancer. 2019 Sep 5;19(1):887. doi: 10.1186/s12885-019-6110-6.

6.

Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.

Ilmer M, Schiergens TS, Renz BW, Schneider C, Sargut M, Waligora R, Weniger M, Hartwig W, Ceyhan GO, Friess H, Werner J, D'Haese JG.

Surg Oncol. 2019 Aug 26;31:16-21. doi: 10.1016/j.suronc.2019.08.010. [Epub ahead of print]

PMID:
31473583
7.

Targeting nNOS ameliorates the severe neuropathic pain due to chronic pancreatitis.

Demir IE, Heinrich T, Carty DG, Saricaoglu ÖC, Klauss S, Teller S, Kehl T, Mota Reyes C, Tieftrunk E, Lazarou M, Bahceci DH, Gökcek B, Ucurum BE, Maak M, Diakopoulos KN, Lesina M, Schemann M, Erkan M, Krüger A, Algül H, Friess H, Ceyhan GO.

EBioMedicine. 2019 Aug;46:431-443. doi: 10.1016/j.ebiom.2019.07.055. Epub 2019 Aug 8.

8.

Venous resection during pancreatectomy for pancreatic cancer: a systematic review.

Wang X, Demir IE, Schorn S, Jäger C, Scheufele F, Friess H, Ceyhan GO.

Transl Gastroenterol Hepatol. 2019 Jun 19;4:46. doi: 10.21037/tgh.2019.06.01. eCollection 2019. Review.

9.

Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer.

Scheufele F, Hartmann D, Friess H.

Transl Gastroenterol Hepatol. 2019 May 17;4:32. doi: 10.21037/tgh.2019.04.09. eCollection 2019. Review.

10.

Multiple intestinal intussusceptions caused by highly impaired gastrointestinal motility in a patient with chronic cannabis consumption.

Prokopchuk O, Neumann PA, Hüser N, Friess H, Wilhelm D.

J Surg Case Rep. 2019 May 23;2019(5):rjz160. doi: 10.1093/jscr/rjz160. eCollection 2019 May.

11.

Correction to: Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.

Zhang M, Pan Y, Tang D, Dorfman RG, Xu L, Zhou Q, Zhou L, Wang Y, Li Y, Yin Y, Kong B, Friess H, Zhao S, Wu JL, Wang L, Zou X.

Cell Commun Signal. 2019 May 6;17(1):43. doi: 10.1186/s12964-019-0357-z.

12.

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.

Münch S, Pigorsch SU, Devečka M, Dapper H, Feith M, Friess H, Weichert W, Jesinghaus M, Braren R, Combs SE, Habermehl D.

Radiat Oncol. 2019 Apr 16;14(1):66. doi: 10.1186/s13014-019-1270-8.

13.

Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.

Ding X, Zhang Y, Huang T, Xu G, Peng C, Chen G, Kong B, Friess H, Shen S, Lv Y, Roberts LR, Wang L, Zou X.

Am J Cancer Res. 2019 Mar 1;9(3):546-561. eCollection 2019.

14.

18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches.

Kornberg A, Friess H.

Therap Adv Gastroenterol. 2019 Mar 19;12:1756284819836205. doi: 10.1177/1756284819836205. eCollection 2019. Review.

15.

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study.

De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, Geisler F, Ricke J, Paprottka P, Friess H, Werner J, Gerbes AL, Mayerle J, Engel J.

Gut. 2019 Mar 16. pii: gutjnl-2018-318193. doi: 10.1136/gutjnl-2018-318193. [Epub ahead of print]

16.

A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.

Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T.

Theranostics. 2019 Feb 12;9(5):1280-1287. doi: 10.7150/thno.29247. eCollection 2019.

17.

Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.

Zhang M, Pan Y, Tang D, Dorfman RG, Xu L, Zhou Q, Zhou L, Wang Y, Li Y, Yin Y, Kong B, Friess H, Zhao S, Wu JL, Wang L, Zou X.

Cell Commun Signal. 2019 Mar 12;17(1):23. doi: 10.1186/s12964-019-0332-8. Erratum in: Cell Commun Signal. 2019 May 6;17(1):43.

18.

Mortality and postoperative complications after different types of surgical reconstruction following pancreaticoduodenectomy-a systematic review with meta-analysis.

Schorn S, Demir IE, Vogel T, Schirren R, Reim D, Wilhelm D, Friess H, Ceyhan GO.

Langenbecks Arch Surg. 2019 Mar;404(2):141-157. doi: 10.1007/s00423-019-01762-5. Epub 2019 Feb 28.

PMID:
30820662
19.

Cellular Dissociation Grading Based on the Parameters Tumor Budding and Cell Nest Size in Pretherapeutic Biopsy Specimens Allows for Prognostic Patient Stratification in Esophageal Squamous Cell Carcinoma Independent From Clinical Staging.

Jesinghaus M, Brühl F, Steiger K, Klare P, Reiser M, Scheiter A, Konukiewitz B, Kuhn P, Münch S, Quante M, Schmid RM, Wilhelm D, Feith M, Friess H, Combs SE, Saur D, Boxberg M, Weichert W.

Am J Surg Pathol. 2019 May;43(5):618-627. doi: 10.1097/PAS.0000000000001230.

PMID:
30807302
20.

Brg1 promotes liver regeneration after partial hepatectomy via regulation of cell cycle.

Wang B, Kaufmann B, Engleitner T, Lu M, Mogler C, Olsavszky V, Öllinger R, Zhong S, Geraud C, Cheng Z, Rad RR, Schmid RM, Friess H, Hüser N, Hartmann D, von Figura G.

Sci Rep. 2019 Feb 20;9(1):2320. doi: 10.1038/s41598-019-38568-w.

21.

[Model-based treatment in surgery].

Vogel T, Kohn N, Ostler D, Marahrens N, Samm N, Jell A, Kranzfelder M, Wilhelm D, Friess H, Feußner H.

Chirurg. 2019 Jun;90(6):470-477. doi: 10.1007/s00104-019-0815-6. Review. German.

PMID:
30758596
22.

Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological infiltration.

Kaissis GA, Lohöfer FK, Ziegelmayer S, Danner J, Jäger C, Schirren R, Ankerst D, Ceyhan GO, Friess H, Rummeny EJ, Weichert W, Braren RF.

PLoS One. 2019 Jan 2;14(1):e0208717. doi: 10.1371/journal.pone.0208717. eCollection 2019.

23.

Fullness or Distension of Proximal Jejunum: A Risk Factor Contributing to the Delayed Gastric Emptying.

Tang WH, Shi X, Fan X, Chen WD, You CZ, Friess H.

Am Surg. 2018 Jun 1;84(6):e185-e187. No abstract available.

PMID:
30454532
24.

Ductal obstruction promotes formation of preneoplastic lesions from the pancreatic ductal compartment.

Cheng T, Zhang Z, Jian Z, Raulefs S, Schlitter AM, Steiger K, Maeritz N, Zhao Y, Shen S, Zou X, Ceyhan GO, Friess H, Kleeff J, Michalski CW, Kong B.

Int J Cancer. 2019 May 15;144(10):2529-2538. doi: 10.1002/ijc.31981. Epub 2018 Dec 12.

PMID:
30412288
25.

Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Kaufmann B, Hartmann D, D'Haese JG, Stupakov P, Radenkovic D, Gloor B, Friess H.

Dig Surg. 2019;36(6):455-461. doi: 10.1159/000493466. Epub 2018 Nov 8. Review.

26.

Influence of the surgical technique on survival in the treatment of carcinomas of the true cardia (Siewert Type II) - Right thoracoabdominal vs. transhiatal-abdominal approach.

Tosolini C, Reim D, Schirren R, Feith M, Friess H, Novotny AR.

Eur J Surg Oncol. 2019 Mar;45(3):416-424. doi: 10.1016/j.ejso.2018.09.017. Epub 2018 Oct 17.

PMID:
30396809
27.

Cancer clinical trials - Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC).

Kessel KA, Vogel MME, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, von Eisenhart-Rothe R, Meyer B, Kiechle M, Keller U, Peschel C, Bassermann F, Schmid R, Schwaiger M, Combs SE.

Clin Transl Radiat Oncol. 2018 Oct 4;13:44-49. doi: 10.1016/j.ctro.2018.10.001. eCollection 2018 Nov.

28.

Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.

Sperlich A, Balmert A, Doll D, Bauer S, Franke F, Keller G, Wilhelm D, Mur A, Respondek M, Friess H, Nitsche U, Janssen KP.

BMC Cancer. 2018 Oct 19;18(1):998. doi: 10.1186/s12885-018-4940-2.

29.

Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.

Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K.

Dig Dis Sci. 2019 Jan;64(1):269-280. doi: 10.1007/s10620-018-5296-9. Epub 2018 Sep 27.

PMID:
30259282
30.

Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.

Jian Z, Cheng T, Zhang Z, Raulefs S, Shi K, Steiger K, Maeritz N, Kleigrewe K, Hofmann T, Benitz S, Bruns P, Lamp D, Jastroch M, Akkan J, Jäger C, Huang P, Nie S, Shen S, Zou X, Ceyhan GO, Michalski CW, Friess H, Kleeff J, Kong B.

Cell Mol Gastroenterol Hepatol. 2018 Jul 26;6(4):429-449. doi: 10.1016/j.jcmgh.2018.07.003. eCollection 2018.

31.

Cytosolic nucleic acid sensors of the innate immune system promote liver regeneration after partial hepatectomy.

Schulze S, Stöß C, Lu M, Wang B, Laschinger M, Steiger K, Altmayr F, Friess H, Hartmann D, Holzmann B, Hüser N.

Sci Rep. 2018 Aug 16;8(1):12271. doi: 10.1038/s41598-018-29924-3.

32.

Peroxisome Proliferator-Activated Receptor gamma negatively regulates liver regeneration after partial hepatectomy via the HGF/c-Met/ERK1/2 pathways.

Cheng Z, Liu L, Zhang XJ, Lu M, Wang Y, Assfalg V, Laschinger M, von Figura G, Sunami Y, Michalski CW, Kleeff J, Friess H, Hartmann D, Hüser N.

Sci Rep. 2018 Aug 8;8(1):11894. doi: 10.1038/s41598-018-30426-5.

33.

Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.

Münch S, Pigorsch SU, Devečka M, Dapper H, Weichert W, Friess H, Braren R, Combs SE, Habermehl D.

Radiat Oncol. 2018 Aug 2;13(1):139. doi: 10.1186/s13014-018-1085-z.

34.

Nutritional support and therapy in pancreatic surgery: A position paper of the International Study Group on Pancreatic Surgery (ISGPS).

Gianotti L, Besselink MG, Sandini M, Hackert T, Conlon K, Gerritsen A, Griffin O, Fingerhut A, Probst P, Abu Hilal M, Marchegiani G, Nappo G, Zerbi A, Amodio A, Perinel J, Adham M, Raimondo M, Asbun HJ, Sato A, Takaori K, Shrikhande SV, Del Chiaro M, Bockhorn M, Izbicki JR, Dervenis C, Charnley RM, Martignoni ME, Friess H, de Pretis N, Radenkovic D, Montorsi M, Sarr MG, Vollmer CM, Frulloni L, Büchler MW, Bassi C.

Surgery. 2018 Nov;164(5):1035-1048. doi: 10.1016/j.surg.2018.05.040. Epub 2018 Jul 17.

PMID:
30029989
35.

Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma.

Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M, Schirren RM, Friess H, Ceyhan GO.

BJS Open. 2018 Mar 30;2(2):52-61. doi: 10.1002/bjs5.46. eCollection 2018 Apr. Review.

36.

SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism.

Li Y, Zhang M, Dorfman RG, Pan Y, Tang D, Xu L, Zhao Z, Zhou Q, Zhou L, Wang Y, Yin Y, Shen S, Kong B, Friess H, Zhao S, Wang L, Zou X.

Neoplasia. 2018 Jul;20(7):745-756. doi: 10.1016/j.neo.2018.03.008. Epub 2018 Jun 17.

37.

Pancreatic stump closure techniques and pancreatic fistula formation after distal pancreatectomy: Meta-analysis and single-center experience.

Tieftrunk E, Demir IE, Schorn S, Sargut M, Scheufele F, Calavrezos L, Schirren R, Friess H, Ceyhan GO.

PLoS One. 2018 Jun 13;13(6):e0197553. doi: 10.1371/journal.pone.0197553. eCollection 2018.

38.

Genetically induced vs. classical animal models of chronic pancreatitis: a critical comparison.

Klauss S, Schorn S, Teller S, Steenfadt H, Friess H, Ceyhan GO, Demir IE.

FASEB J. 2018 Jun 4:fj201800241RR. doi: 10.1096/fj.201800241RR. [Epub ahead of print]

PMID:
29863911
39.

Enhanced Visualization: From Intraoperative Tissue Differentiation to Augmented Reality.

Wilhelm D, Vogel T, Ostler D, Marahrens N, Kohn N, Koller S, Friess H, Kranzfelder M.

Visc Med. 2018 Feb;34(1):52-59. doi: 10.1159/000485940. Epub 2018 Feb 16. Review.

40.

Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study.

Klompmaker S, van Hilst J, Gerritsen SL, Adham M, Teresa Albiol Quer M, Bassi C, Berrevoet F, Boggi U, Busch OR, Cesaretti M, Dalla Valle R, Darnis B, De Pastena M, Del Chiaro M, Grützmann R, Diener MK, Dumitrascu T, Friess H, Ivanecz A, Karayiannakis A, Fusai GK, Labori KJ, Lombardo C, López-Ben S, Mabrut JY, Niesen W, Pardo F, Perinel J, Popescu I, Roeyen G, Sauvanet A, Prasad R, Sturesson C, Lesurtel M, Kleeff J, Salvia R, Besselink MG; E-AHPBA DP-CAR study group.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):988. doi: 10.1245/s10434-018-6442-5.

PMID:
29560574
41.

3D Cancer Migration Assay with Schwann Cells.

Fangmann L, Teller S, Stupakov P, Friess H, Ceyhan GO, Demir IE.

Methods Mol Biol. 2018;1739:317-325. doi: 10.1007/978-1-4939-7649-2_20.

PMID:
29546716
42.

The impact of surgically placed, intraperitoneal drainage on morbidity and mortality after pancreas resection- A systematic review & meta-analysis.

Schorn S, Nitsche U, Demir IE, Scheufele F, Tieftrunk E, Schirren R, Klauss S, Sargut M, Ceyhan GO, Friess H.

Pancreatology. 2018 Apr;18(3):334-345. doi: 10.1016/j.pan.2018.02.013. Epub 2018 Feb 23. Review.

PMID:
29534868
43.

Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study.

Klompmaker S, van Hilst J, Gerritsen SL, Adham M, Teresa Albiol Quer M, Bassi C, Berrevoet F, Boggi U, Busch OR, Cesaretti M, Dalla Valle R, Darnis B, De Pastena M, Del Chiaro M, Grützmann R, Diener MK, Dumitrascu T, Friess H, Ivanecz A, Karayiannakis A, Fusai GK, Labori KJ, Lombardo C, López-Ben S, Mabrut JY, Niesen W, Pardo F, Perinel J, Popescu I, Roeyen G, Sauvanet A, Prasad R, Sturesson C, Lesurtel M, Kleeff J, Salvia R, Besselink MG; E-AHPBA DP-CAR study group.

Ann Surg Oncol. 2018 May;25(5):1440-1447. doi: 10.1245/s10434-018-6391-z. Epub 2018 Mar 12. Erratum in: Ann Surg Oncol. 2018 Mar 20;:.

44.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6.

PMID:
29508762
45.

Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer.

Mutgan AC, Besikcioglu HE, Wang S, Friess H, Ceyhan GO, Demir IE.

Mol Cancer. 2018 Feb 23;17(1):66. doi: 10.1186/s12943-018-0806-0. Review.

46.

Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment.

Ansari D, Friess H, Bauden M, Samnegård J, Andersson R.

Oncotarget. 2018 Jan 6;9(5):6644-6651. doi: 10.18632/oncotarget.24019. eCollection 2018 Jan 19. Review.

47.

Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.

Prokopchuk O, Grünwald B, Nitsche U, Jäger C, Prokopchuk OL, Schubert EC, Friess H, Martignoni ME, Krüger A.

BMC Cancer. 2018 Feb 2;18(1):128. doi: 10.1186/s12885-018-4055-9.

48.

A look at the progress of treating pancreatic cancer over the past 20 years.

Goess R, Friess H.

Expert Rev Anticancer Ther. 2018 Mar;18(3):295-304. doi: 10.1080/14737140.2018.1428093. Epub 2018 Jan 16. Review.

PMID:
29334794
49.

[Peri- and postoperative nutrition in colorectal cancer patients].

Reischl S, Wilhelm DF, Neumann PA, Friess H, Martignoni ME.

Ther Umsch. 2018;75(10):642-648. doi: 10.1024/0040-5930/a001052. German.

PMID:
31232664
50.

Supplemental Content

Loading ...
Support Center